The Bidirectional Relationship Between Cardiovascular Medications and Oral and Gut Microbiome Health: A Comprehensive...

Area of Science:

• Microbiome research
• Pharmacology
• Cardiovascular medicine

Background:

• Cardiovascular diseases (CVDs) are a major cause of illness and death globally.
• Differences in gut and oral microbiomes are observed between CVD patients and healthy individuals.
• CVD patients often require long-term medications, whose impact on the microbiome is under investigation.

Purpose of the Study:

• To review the existing evidence on the interaction between cardiovascular drugs and the oral and gut microbiomes.
• To highlight the influence of these interactions on drug metabolism and patient response.
• To identify gaps in current research and emphasize the need for further investigation.

Main Methods:

• Literature review of studies investigating the impact of cardiovascular medications on gut and oral microbiomes.
• Analysis of research on specific drug classes, such as statins and beta-blockers.
• Synthesis of findings regarding microbiome dysbiosis and its clinical implications.

Main Results:

• Certain cardiovascular drugs, notably statins and beta-blockers, are associated with gut and oral microbial dysbiosis.
• Microbiome alterations can affect the metabolism and absorption of CVD medications, leading to varied drug responses.
• Emerging evidence suggests a link between microbiome changes and treatment efficacy, necessitating personalized approaches.

Conclusions:

• The interplay between cardiovascular medications and the microbiome is a critical factor in treatment outcomes.
• Understanding these interactions is essential for developing personalized medicine strategies in CVD management.
• More research is required to establish definitive cause-and-effect relationships and clinical significance.